BURLONE, MICHELA Emma
 Distribuzione geografica
Continente #
EU - Europa 947
NA - Nord America 795
AS - Asia 274
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 2.024
Nazione #
US - Stati Uniti d'America 792
IE - Irlanda 296
SE - Svezia 139
IT - Italia 136
DE - Germania 124
UA - Ucraina 93
CN - Cina 79
FR - Francia 75
IN - India 63
HK - Hong Kong 60
SG - Singapore 55
FI - Finlandia 40
BE - Belgio 14
GB - Regno Unito 10
VN - Vietnam 10
CZ - Repubblica Ceca 8
IR - Iran 6
KE - Kenya 5
CA - Canada 3
NL - Olanda 3
PL - Polonia 3
CH - Svizzera 2
EU - Europa 2
RU - Federazione Russa 2
AM - Armenia 1
BG - Bulgaria 1
CL - Cile 1
RO - Romania 1
Totale 2.024
Città #
Dublin 293
Jacksonville 175
Chandler 89
Dearborn 82
Ann Arbor 67
Hong Kong 60
Wilmington 54
Singapore 42
Piemonte 39
Princeton 34
Lawrence 33
Novara 28
Beijing 25
San Mateo 18
Andover 14
Brussels 14
Ashburn 11
Munich 11
Dong Ket 10
Nanjing 9
Brno 8
Bremen 7
Hefei 7
Houston 7
Santa Clara 7
Jinan 5
Kunming 5
Milan 5
Nairobi 5
Seattle 5
Augusta 4
Boardman 4
Helsinki 4
Leawood 4
Monmouth Junction 4
Rome 4
Turin 4
Woodbridge 4
Cassano Magnago 3
Fairfield 3
Kraków 3
Norwalk 3
Strasbourg 3
Ardabil 2
Cassano 2
Chongqing 2
Cumiana 2
Frankfurt am Main 2
Ghemme 2
Guangzhou 2
Hangzhou 2
Los Angeles 2
Lucca 2
Moncalieri 2
Mülheim 2
Ningbo 2
Palermo 2
Shanghai 2
Torino 2
Verona 2
Viareggio 2
Winnipeg 2
Zurich 2
Amsterdam 1
Bangalore 1
Baotou 1
Berlin 1
Busalla 1
Casaleggio Novara 1
Cutrofiano 1
Domodossola 1
Düsseldorf 1
Espoo 1
Forno Canavese 1
Fuzhou 1
Gorgonzola 1
Grafing 1
Hebei 1
Irkutsk 1
Islington 1
Jiaxing 1
Kemerovo 1
Kolkata 1
Lodi 1
Minneapolis 1
Moneglia 1
Mumbai 1
Nanchang 1
Nanning 1
Nichelino 1
Nuremberg 1
Olcenengo 1
Ortonovo 1
Pisa 1
Pozzuolo 1
Quinto di Treviso 1
Quzhou 1
Sacramento 1
San Giusto Canavese 1
Taiyuan 1
Totale 1.293
Nome #
B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD) 97
Red cell distribution width and platelet count as biomarkers of pulmonary arterial hypertension in patients with connective tissue disorders 80
Influence of age on sex-related differences among patients with hepatitis C. 79
Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis 76
Interferon alpha concentrations in blood and peritoneal fluid during treatment for hepatitis C 75
Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma 68
Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents 68
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study 67
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib 67
Response rates to direct antiviral agents among hepatitis C virus infected patients who develop hepatocellular carcinoma following direct antiviral agents treatment 67
[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy] 67
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma 62
Cardiac dysfunction as an early predictor of portal hypertension in chronic hepatitis C 62
Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C 61
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma 61
IL28B Polymorphism, Blood Interferon-alpha Concentration, and Disease Stage of HCV Mono-infected and HCV-HIV Co-infected Patients. 60
Fibrosis Progression in HCV Carriers with Mild Hepatitis Who Possess the High-Repetition Variant of the DRD4 Gene, a Genetic Marker for Binge-Drinking and Risk-Seeking Behavior: A Longitudinal Study. 60
Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients 59
Liver stiffness, not fat liver content, predicts the length of QTc interval in patients with chronic liver disease 57
Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease 56
The albumin–bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development 54
Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naïve patients with chronic lymphocytic leukemia 53
Interferon-stimulated gene pathways in the treatment of viral hepatitis 52
HBV AND LYMPHOMAGENESIS: NOVEL INSIGHTS INTO AN OCCULT RELATIONSHIP 51
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study 50
GENETIC POLYMORPHISM AT THE APOLIPOPROTEIN E LOCUS AFFECTS THE OUTCOME OF CHRONIC HEPATITIS B 49
Recent advances in HCV entry 48
Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. 46
Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression 45
Toxocara encephalitis presenting with autonomous nervous system involvement 42
PANCREATOBILIARY REFLUX RESULTING IN PANCREATIC ASCITES AND CHOLEPERITONEUM AFTER GALLBLADDER PERFORATION 41
HSD17B13 and other liver fat-modulating genes predict development of hepatocellular carcinoma among HCV-positive cirrhotics with and without viral clearance after DAA treatment 39
17β-Oestradiol Protects from Hepatitis C Virus Infection through Induction of Type I Interferon 34
Direct antivirals and cognitive impairment in hepatitis C: a clinical-neurophysiologic study 34
B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD) 30
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 20
Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and Bayesian analysis 15
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 11
Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development 9
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis 8
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 2
Totale 2.082
Categoria #
all - tutte 11.538
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.538


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020398 0 0 0 0 59 56 91 23 47 83 32 7
2020/2021273 31 4 31 3 46 23 37 3 35 11 35 14
2021/2022234 4 13 31 18 15 2 20 12 16 22 32 49
2022/2023641 60 33 41 7 44 62 17 36 307 1 23 10
2023/2024240 24 39 21 0 35 2 42 6 1 4 27 39
2024/202577 17 3 41 7 9 0 0 0 0 0 0 0
Totale 2.082